Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs
- 2 December 2017
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 41 (4) , 363-376
Abstract
Several different types of drugs acting on the central nervous system (CNS) have previously been associated with an increased risk of suicide and suicidal ideation (broadly referred to as suicide). However, a differential association between brand and generic CNS drugs and suicide has not been reported.Keywords
Funding Information
- U.S. Food and Drug Administration (U01FD005272, HHSF2232015101102C)
- National Institutes of Health (2R01GM097618-04)
This publication has 41 references indexed in Scilit:
- Data Mining of the Public Version of the FDA Adverse Event Reporting SystemInternational Journal of Medical Sciences, 2013
- Switching from Brand‐Name to Generic Psychotropic Medications: A Literature ReviewCNS Neuroscience & Therapeutics, 2010
- Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switchingInternational Clinical Psychopharmacology, 2010
- Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post‐marketing clinical study on healthy volunteersBritish Journal of Clinical Pharmacology, 2009
- Patients’ Perceptions Of Generic MedicationsHealth Affairs, 2009
- Suicidal Adverse Events in Pediatric Randomized, Controlled Clinical Trials of Antidepressant Drugs Are Associated with Active Drug Treatment: AMeta-AnalysisJournal of Child and Adolescent Psychopharmacology, 2006
- Perspectives on the Use of Data Mining in PharmacovigilanceDrug Safety, 2005
- Hazard Ratio in Clinical TrialsAntimicrobial Agents and Chemotherapy, 2004
- Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefitPharmacoepidemiology and Drug Safety, 2003
- The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugsClinical Therapeutics, 2003